Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 18

1529P - Fruquinitinib combined with nab-paclitaxel and gemcitabine (AG) as the first-line treatment for pancreatic ductal adenocarcinoma (PDAC) with liver metastases: An open-label, single-arm, single-center phase II clinical study

Date

14 Sep 2024

Session

Poster session 18

Topics

Clinical Research;  Targeted Therapy

Tumour Site

Pancreatic Adenocarcinoma

Presenters

Miaoyan Wei

Citation

Annals of Oncology (2024) 35 (suppl_2): S923-S936. 10.1016/annonc/annonc1605

Authors

M. Wei, S. Shi, J. Li, N. Du, X. Yu, J. Xu

Author affiliations

  • Department Of Pancreatic Surgery And Comprehensive Treatment Of Pancreatic Tumors, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1529P

Background

PDAC with liver metastases remains a significant challenge with poor prognosis. While AG has emerged as a first-line standard treatment, the efficacy was not that satisfying. This trial aims to investigate the efficacy and safety of the combination of fruquintinib and AG on PDAC patients (pts) with liver metastases.

Methods

PDAC pts with liver metastases, who had not received systemic therapy, aged ≥18 years, Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 were included. Enrolled pts received fruquintinib 4mg po, d1-d14, gemcitabine 1000 mg/m2, i.v and d1, 8, 15,nab-paclitaxel 125 mg/m2, i.v, d1,8,15, q4w. The primary endpoint was objective response rate (ORR, RECIST 1.1), and the secondary endpoints were progression-free survival (PFS), disease control rate (DCR), overall survival (OS) and adverse events (AEs) etc.

Results

Between Aug. 2021 and May 2023, a total of 30 pts were included. 26 pts were evaluable and the mean age was 58.7 years (30-73) and equal gender representation. The primary origin was in pancreatic head (42%), body/neck (35%), and tail (23%). 5 pts harbored distant metastases beyond the liver. 15 achieved partial response and 4 had stable disease, yielding a confirmed ORR of 57.7% (95% CI: 38.7%, 76.7%) and a DCR of 73.1% (95% CI: 56.0%, 90.1%). With a median follow-up time of 10 months (95% CI: 7-12), the median PFS reached 8 months (95% CI: 4-8) while the OS data was not yet mature for final analysis. 7 pts underwent surgery with R0 resections of primary lesion. The most frequent treatment-emergent AEs (TEAEs) included decreased WBC (100%), fatigue (88.46%), hyperglycaemia (84.62%), hypercholesterolaemia (73.08%), decreased PLT (69.23%), and hypertriglyceridaemia (46.15%). Grade 3/4 TEAEs were mainly decreased WBC, PLT, and RBC (each 11.5%). 2 (7.7%) pts experienced SAEs (gastrointestinal hemorrhage).

Conclusions

The combination of fruquintinib and AG regimen has demonstrated promising efficacy and tolerable toxicity in the first-line treatment of PDAC with liver metastases and holds potential as a conversion therapy strategy for these pts.

Clinical trial identification

NCT05168527.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.